IP Library Granted Patent US 8,940,742
Granted Patent B2
US 8,940,742 · App. 13/841,265 · Granted Jan 27, 2015

Heterocyclic compounds and uses thereof

Inventors: Alfredo C. Castro (Winchester, MA); Katrina Chan (Fremont, CA); Catherine A. Evans (Somerville, MA); Somarajannair Janardanannair (Woburn, MA); Andre Lescarbeau (Somerville, MA); Liansheng Li (San Diego, CA); Tao Liu (Ashland, MA); Yi Liu (San Diego, CA); Pingda Ren (San Diego, CA); Daniel A. Snyder (Somerville, MA); Martin R. Tremblay (Melrose, MA)
Assignee: Infinity Pharmaceuticals, Inc.
C07D401/12C07D487/04C07D405/12C07D491/056C07D401/14C07D217/24C07D413/12C07D417/12C07D471/04C07D495/04C07D403/12C07D217/26C07D401/04C07D417/14C07D491/048C07D513/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,940,742
App. No.
13/841,265
Granted
Jan 27, 2015
Kind
B2
Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Claims (94)

1. A compound of Formula (I):

or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof,

or a pharmaceutically acceptable form thereof, wherein

Cy is 6-membered aryl substituted by 1 occurrence of R 3 and 0, 1, 2, or 3 occurrence(s) of R 5 ;

W b 5 is CR 8 or CHR 8 ;

R 8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl or nitro;

B is hydrogen, alkyl, amino, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 occurrence(s) of R 2 ;

each R 2 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, or carbonate;

X is —(CH(R 9 )) z —;

Y is —NH—C(═O)—, —C(═O)—N(R 9 )—, or —C(═O)—N(R 9 )—(CHR 9 )—;

z is an integer of 1, 2, 3, or 4;

R 3 is alkyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfinyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, aryl, heteroaryl, hydroxyl, or nitro;

each R 5 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl, or nitro;

each R 9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or heteroalkyl; or two adjacent occurrences of R 9 together with the atoms to which they are attached form a 4- to 7-membered ring;

W d is

X 1 , X 2 and X 3 are each independently C, CR 13 , or N;

X 4 , X 5 and X 6 are each independently N, NH, CR 13 , S, or O; and

wherein R 10 , R 11 , R 12 , and R 13 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

2. The compound of claim 1 , having Formula (IIIb):

wherein R 8 is hydrogen, alkyl, cyano, or halo; R 9 is hydrogen or alkyl, and

Y is —NH—C(O)—.

3. The compound of claim 1 , having a structure of Formula (II):

4. The compound of claim 1 , having a structure of Formula (IIIa) or Formula (IIIb):

5. The compound of claim 1 , wherein R 3 is halo, cyano, hydroxy, alkyl, alkoxy, amino, acyl, heteroaryl, aryl, heterocyclyl, or cycloalkyl.

6. The compound of claim 5 , wherein R 3 is heteroaryl, aryl, alkyl, haloalkyl, OH, Cl, or F.

7. The compound of claim 6 , wherein R 3 is heteroaryl, phenyl, CH 3 , CF 3 , OH, or Cl.

8. The compound of claim 5 , wherein R 3 is CH 3 , OCH 3 , CF 3 , or halo.

9. The compound of claim 5 , wherein R 3 is OCF 3 , CN, cyclopropyl, CH 2 OH, amino, formyl, or heterocyclyl.

10. The compound of claim 1 , wherein R 8 is H, CH 3 , OCH 3 , CF 3 , CN, or halo.

11. The compound of claim 1 , wherein B is aryl, heteroaryl, alkyl, cycloalkyl, or heterocyclyl, each of which is substituted with 0, 1, 2, or 3 occurrence(s) of R 2 .

12. The compound of claim 1 , wherein B is phenyl substituted with 0, 1, 2, or 3 occurrence(s) of R 2 .

13. The compound of claim 1 , wherein B is unsubstituted phenyl.

14. The compound of claim 1 , wherein B is phenyl substituted with 1 or 2 occurrence(s) of R 2 .

15. The compound of claim 14 , wherein R 2 is halo or alkyl.

16. The compound of claim 1 , wherein B is methyl, isopropyl, or cyclopropyl.

17. The compound of claim 1 , wherein B is cyclohexyl or alkyl.

18. The compound of claim 1 , wherein W d is:

wherein one of X 1 and X 2 is N and one of X 1 and X 2 is C or CR 13 ; and X 3 is CR 13 or N.

19. The compound of claim 1 , wherein W d is:

20. The compound of claim 1 , wherein W d is:

21. The compound of claim 1 , wherein W d is:

22. The compound of claim 1 , wherein W d is:

23. The compound of claim 1 , wherein W d is:

24. The compound of claim 1 , wherein W d is

25. The compound of claim 18 , wherein R 10 is NH 2 .

26. The compound of claim 1 , wherein X is —CH 2 — or —CH(CH 3 )—.

27. The compound of claim 26 , wherein X is —CH(CH 3 )—.

28. The compound of claim 27 , wherein the CH carbon of the —CH(CH 3 )— moiety has an (S) stereochemical configuration.

29. The compound of claim 27 , wherein the CH carbon of the —CH(CH 3 )— moiety has an (R) stereochemical configuration.

30. The compound of claim 1 , wherein Y is —NH—C(O)—.

31. The compound of claim 1 , wherein —X—Y— is —CH 2 —N(CH 3 )—C(O)—.

32. The compound of claim 1 , wherein —X—Y— is (S)—CH(CH 3 )—NH—C(O)—.

33. The compound of claim 1 , wherein —X—Y— is (R)—CH(CH 3 )—NH—C(O)—.

34. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient, diluent, or carrier.

35. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

36. The compound of claim 35 , wherein the compound is

or a pharmaceutically acceptable form thereof.

37. The compound of claim 36 , wherein the compound is

Compound 116,

or a pharmaceutically acceptable form thereof.

38. The compound of claim 36 , wherein the compound is

or a pharmaceutically acceptable form thereof.

39. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

40. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

41. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

42. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

43. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

44. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable form thereof.

45. A compound of Formula (II):

or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof,

or a pharmaceutically acceptable form thereof, wherein

R 8 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfonamido, halo, cyano, hydroxyl or nitro;

B is hydrogen, alkyl, amino, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 occurrence(s) of R 2 ;

each R 2 is independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, or carbonate;

X is —(CH(R 9 )) z —;

Y is —N(R 9 )—C(═O)—, —C(═O)—N(R 9 )—, or —C(═O)—N(R 9 )—(CHR 9 )—;

z is an integer of 1, 2, 3, or 4;

R 3 is alkyl, cycloalkyl, heterocyclyl, fluoroalkyl, heteroalkyl, alkoxy, amido, amino, acyl, acyloxy, sulfinyl, sulfonyl, sulfoxide, sulfone, sulfonamido, halo, cyano, aryl, heteroaryl, hydroxyl, or nitro;

each R 9 is independently hydrogen, alkyl, cycloalkyl, heterocyclyl, or heteroalkyl; or two adjacent occurrences of R 9 together with the atoms to which they are attached form a 4- to 7-membered ring;

W d is

X 1 , X 2 and X 3 are each independently C, CR 13 , or N;

X 4 , X 5 and X 6 are each independently N, NH, CR 13 , S, or O; and

wherein R 10 , R 11 , R 12 , and R 13 are each independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocyclyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, nitro, phosphate, urea, carbonate, or NR′R″ wherein R′ and R″ are taken together with nitrogen to form a cyclic moiety.

46. A pharmaceutical composition comprising a compound of claim 37 , and a pharmaceutically acceptable excipient, diluent, or carrier.

47. A pharmaceutical composition comprising a compound of claim 38 , and a pharmaceutically acceptable excipient, diluent, or carrier.

48. The compound of claim 45 , wherein the compound is

or a pharmaceutically acceptable form thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2024
From: INFINITY PHARMACEUTICALS, INC.
To: TWELVE THERAPEUTICS, INC.
Reel/Frame 069193/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2013
From: CHAN, KATRINA; LI, LIANSHENG; LIU, YI; REN, PINGDA
To: INTELLIKINE LLC
Reel/Frame 030992/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: CASTRO, ALFREDO C.; EVANS, CATHERINE A.; JANARDANANNAIR, SOMARAJANNAIR; LESCARBEAU, ANDRE; LIU, TAO; SNYDER, DANIEL A.; TREMBLAY, MARTIN R.
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 030735/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2013
From: INTELLIKINE LLC
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 030590/0539 →
Continuity (3)
Provisional Application 61622259 · Apr 10, 2012
Provisional Application 61713404 · Oct 12, 2012
Related Publication 20130267521A1 · Oct 10, 2013